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ABSTRACT
In humans, low serum carnosinase (CN1) activity protects patients with type 2 diabetes from diabetic
nephropathy. We now characterized the interaction of thiol-containing compounds with CN1 cysteine resi-
due at position 102, which is important for CN1 activity. Reduced glutathione (GSH), N-acetylcysteine and
cysteine (3.2 ± 0.4, 2.0 ±0.3, 1.6 ± 0.2mmol/mg/h/mM; p< .05) lowered dose-dependently recombinant CN1
(rCN1) efficiency (5.2 ± 0.2mmol/mg/h/mM) and normalized increased CN1 activity renal tissue samples of
diabetic mice. Inhibition was allosteric. Substitution of rCN1 cysteine residues at position 102 (Mut1C102S)
and 229 (Mut2C229S) revealed that only cysteine-102 is influenced by cysteinylation. Molecular dynamic
simulation confirmed a conformational rearrangement of negatively charged residues surrounding the zinc
ions causing a partial shift of the carnosine ammonium head and resulting in a less effective pose of the
substrate within the catalytic cavity and decreased activity. Cysteine-compounds influence the dynamic
behaviour of CN1 and therefore present a promising option for the treatment of diabetes.
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Introduction
Carnosinase (CN1, EC 3.4.13.20) plays an important role in the
development of nephropathy in diabetic patients. CN1 is encoded
by the CNDP1 gene1 and susceptibility to diabetic nephropathy
(DN) in patients with diabetes mellitus type II is associated with a
polymorphism in the CNDP1 gene2. The shortest allelic form, the
so-called CNDP1 “Mannheim allele” (D18S880, homozygosity for
the five-leucine allele), is associated with lower serum CN1 activ-
ities and was found to be associated with a lower prevalence of
DN2,3. CN1 belongs to the M20 family of metalloproteases and
cleaves histidine-containing dipeptides, such as carnosine
(b-alanyl-L-histidine) and anserine (b-alanyl-L-1-methylhistidine)1.
Carnosine scavenges carbonyls4–6, inhibits glycation7 and acts as
ACE inhibitor8,9. Its function as antioxidant is debated10–14. It
restores erythrocyte deformability15, inhibits cellular senes-
cence16,17 as well as the production of matrix proteins such as
fibronectin and collagen type VI by podocytes2. Carnosine is
actively absorbed in the gastro-intestinal tract via the hPepT1
transporter and rapidly hydrolysed by CN1 in plasma, which pre-
cludes therapeutic administration of carnosine in humans, e.g. for
treatment of diabetic sequelae18,19. Development of carnosine
derivatives resistant to CN1 hydrolysis has become the subject of
emerging interest in recent years20. In rodents, no serum CN1 is
present and carnosine supplementation of diabetic mice increases
serum and tissue carnosine levels and mitigates DN, reduces renal
vasculopathy21, normalizes vascular permeability21, improves
wound healing22 and decreases insulin growth factor binding pro-
tein-1 (IGFBP1) production through suppression of HIF-1a, and
improves glucose homeostasis23. Moreover, in streptozotocin-
induced diabetic rats, carnosine prevents apoptosis of glomerular
cells, podocyte loss24,25, and vascular damage26.
In contrast to rodents, dietary supply of carnosine does not
increase systemic histidine dipeptide concentrations due to rapid
degradation by CN1 (19). An alternative approach to increase tis-
sue carnosine concentrations and associated protective actions is
pharmacological inhibition of CN1 activity. CN1 is a homodimer
in vitro1, but present as a monomer and a dimer in vivo27. Each
monomer consists of a catalytic domain and a dimerization
domain with the catalytic domain featuring a dinuclear Zn2þ-con-
taining active site28. The age-dependent increase of serum CN1
activity in children and adults29 is not caused by higher CN1 con-
centrations but due to allosteric conformational changes27,30.
Carnosine degradation rate by CN1 is also affected by substrate
inhibition of the CN1 substrates anserine31 and homocarnosine27.
Molecular dynamic (MD) simulations demonstrated that the higher
affinity of homocarnosine is based, at least in part, on more exten-
sive interactions inside the active site of CN128. Cysteine substitu-
tions in the recombinant CN1 indicated the relevance of the
cysteine residue at position 102 (Cys102) for its catalytic activity32.
Carbonylation increases, S-nitrosylation of Cys102 reduces CN1
activity. Under diabetic conditions carbonyl-stress is increased,
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3 concentrations are reduced
32, and CN1 is post
translationally modified, leading to increased renal CN1 activity32.
Glutathione and cysteine are common thiols (R-SH) in mam-
mals. Thiol groups are reducing agents present at intracellular
concentrations of approximately 5mmol/l. Glutathione (c-L-
Glutamyl-L-cysteinylglycine) is present in both the reduced (GSH)
and the oxidized (GSSG) state, with the former redox state allow-
ing donation of reducing equivalents from the thiol group of cyst-
eine. In healthy cells and tissues, more than 90% of the total
glutathione pool is present in the reduced form and the GSH/
GSSG ratio is tightly regulated. Reduction in the GSH/GSSG ratio is
a common signature of diabetes-related oxidative stress and con-
tributes to protein dysfunction33,34. In light of recent findings
showing that renal glutathione concentrations are reduced in dia-
betic conditions, in this present study the question of whether
CN1 activity is influenced by interaction of cysteine residues in
CN1 with glutathione was addressed. In addition, the putative role
of S-cysteinylation by thiol-containing compounds on CN1 activ-
ities was examined along with the underlying mechanism of CN1
regulation, which was investigated by molecular dynamic (MD)
simulations.
Material and methods
Carnosinase activity
CN1 activity was assayed according to the method described by
Teufel and coworkers1. Briefly, the reaction was initiated by add-
ition of carnosine to serum carnosinase at pH of 7. The reaction
was stopped after defined periods by adding 1% trichloracetic
acid (final concentration in the test 0.3%). Liberated histidine was
derivatized by adding o-phtaldialdehyde (OPA) and fluorescence
was read using a MicroTek late reader (kExc 360 nm; kExc 460 nm).
Interaction of OPA with cysteine, GSH or N-acetylcysteine could be
excluded. Vmax values were obtained from Dixon plots using a lin-
ear regression program from five different assays. The kinetic
parameters were determined by using various concentrations of
carnosine, and data fitting was performed according to
Michaelis–Menten equation.
Recombinant CN1 enzyme
Recombinant FLAG-tagged proteins have been purified from CHO
supernatant as described previously32. Briefly, CHO cells were
transfected with expression vector for CN1 wild type. FLAGG-
tagged CN1 was secreted in the supernatant and concentrated
and washed with TBS. Purity of recombinant enzyme was checked
by silver staining. Substitution of cysteine with serine at position
102 and 229 (Mut1C102S and Mut 2C229S) were performed as previ-
ously described32.
Diabetic mice
Male C57BL/KsJm/Leptdb (db/db) mice (Stock 00062) and their
normal normoglycemic herozygous littermates were obtained from
Charles River (Sulzfeld, Germany). The mice were treated as previ-
ous described32. The experimental procedure was approved by the
North Stockholm Ethical Committee for Care and Use of
Laboratory Animals21. Twenty-one-week-old animals were euthan-
ized by carbon-dioxide. The kidneys were removed, immediately
homogenized in cold buffer containing 20mM HEPES, 1mM ethyl-
ene glycol-tetraacetic acid (EGTA), 210mM mannitol and 70mM
sucrose per gram tissue, pH 7.2. The homogenate was centrifuged
at 1500 g for 5min at 4 C, and the supernatant was kept at
80 C until analysis21. Protein concentration was determined by
Bradford Assay.
Set up of the carnosinase–carnosine complex
The resolved structure of CN1 was retrieved from Protein Data
Bank (PDB, http://wwwrcsb.org, Id: 3DLJ) and was initially prepared
by removing water molecules and all crystallization additives.
Since this structure includes a homodimer, the simulations
involved the monomer B which is the monomer with less unre-
solved gaps (gaps: residues 77–79 and 208–209) and with the
higher percentage of residues falling in the allowed regions of the
Ramachandran plot (82.23% vs. 81.95%). The included gaps were
then filled by using the corresponding segments of the previously
reported homology model35 and the completed protein was firstly
minimized by taking fixed all atoms apart from those included
into a 8Å radius sphere around the inserted segments followed
by a minimization with backbone atoms fixed to optimize the
overall protein structure preserving the experimental folding.
The so obtained CN1 structure was then utilized in docking
simulations to generate the complex with carnosine. In detail, the
optimized carnosine structure was built as described in previous
studies36 and docking calculations were performed by PLANTS,
which generates reliable poses by ant colony optimization algo-
rithms37. The search was focused into a 10 Å radius sphere around
the barycenter of the two zinc ions, the calculations produced 20
poses which were scored by using the ChemPLP score function
with speed equal to 1. The so generated best complex was finally
minimized by taking fixed all atoms apart from those included
into a 10 Å radius sphere around the bound ligand.
Set up of the cysteinylated complexes and molecular dynamics
(MD) simulations
The optimized carnosinase–carnosine complex was used to gener-
ate the two corresponding cysteinylated complexes by manually
adding the cysteine structure on Cys102 and Cys229. Since the
two cysteine residues are sufficiently exposed this manual modifi-
cation was performed without difficulty. In this way generated cys-
teinylated proteins were refined by an energy minimization taking
fixed all atoms apart from those included into a 10Å radius sphere
around the inserted cysteine in order to optimize its arrangement
on the protein surface.
The minimized structures were neutralized by adding 21
sodium ions by using the program SODIUM (http://www.ks.uiuc.
edu/Development/MDTools/sodium/) as implemented in the VEGA
suite of programs38 and the neutralized structures underwent a
preliminary minimization keeping fixed the backbone atoms to
optimize the relative position of the sodium ions. The neutralized
structures were then inserted into a 70Å 100Å 70Å water box
containing about 10,200 water molecules. The hydrated systems
underwent energy minimization to optimize the relative pose of
the solvent molecules and the so optimized structures underwent
20 ns molecular dynamics (MD) simulations with the following
characteristics: (a) Newton’s equation was integrated using the
r-RESPA method (every 4 fs for long-range electrostatic forces, 2 fs
for short-range non-bonded forces, and 1 fs for bonded forces);
(b) the simulation space was stabilized by introducing the Periodic
Boundary Conditions (70 Å 100Å 70 Å); (c) the long-range elec-
trostatic potential was treated by the Particle Mesh Ewald summa-
tion method (70 100 70 grid points); (d) the temperature was
maintained at 300 ± 10 K by means of the Langevin’s algorithm;
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(e) Lennard-Jones (L-J) interactions were calculated with a cutoff
of 10Å and the pair list was updated every 20 iterations; (f) a
frame was stored every 10 ps, to yield 2000 frames. The simula-
tions were carried out in two phases: an initial period of heating
from 0 K to 300 K over 300,000 iterations (300 ps, i.e. 1 K/ps) and
the monitored phase of 20 ns. The mentioned minimizations were
performed using the conjugate gradient algorithm until the r.m.s.
gradient was smaller than 0.01 kcal mol-1 Å-1. All calculations were
carried out by NAMD 2.7 with the force-field CHARMm v22 and
Gasteiger’s atomic charges39.
Statistical analysis
A minimum of three independent experiments were performed in
duplicates and more. Data are given as mean± SD. For comparison
of three of more groups a one-way analysis of variance was
performed, followed by post hoc analyses using Tukeys test.
Differences were considered significant at p< .05.
Results
Effect of thiol-containing compounds on CN1 activity
Human serum carnosinase activity
The activity of recombinant CN1 (rCN1), produced in CHO cells,
was concentration-dependently reduced by reduced glutathione
(GSH), cysteine, N-acetylcysteine (Table 1) and cysteine (Figure 1
shows the effect of cysteine). Addition of 1mM thiol-containing
substrate, CN1 activity was reduced, whereas Km values were
hardly affected (Table 1), indicating an allosteric inhibition.
Reduced CN1 activity was achieved by adding 0.2mM cysteine
(p< .001), 0.6mM GSH (p< .01) or 0.4mM N-acetylcysteine
(p< .01). Efficiency of degradation of L-glutamic acid
(5.2 ± 0.2 mmol/mg/h/mM; p¼ns) and glycine (5.8 ± 0.4mmol/mg/h/
mM; p¼ns), components of glutathione and GSSG, had not effect
on CN1 activity (5.2 ± 0.3mmol/mg/h; p¼ ns) with Km values
(Table 1) of comparable value.
Role of cysteinylation
Substitution of both rCN1 cysteine residues at position 102
(Mut1C102S) and 229 (Mut2C229S) showed that cysteine at position
102 but not at position 229 is mandatory for regulation of CN1
activity by thiols. The efficiency for carnosine degradation of
Mut1C102S was not influenced by the addition of cysteine. The
addition of cysteine to rCN1 Mut2C229S significantly reduced CN1
efficiency (1.8 ± 0.6mmol/mg/h/mM; p< .05) compared to the cata-
lytic efficiency of rCN1 in thiol-free medium (5.2 ± 0.2 mmol/mg/h/
mM). The inhibitory effect on catalytic efficiency by cysteine is
comparable for Mut2C229S and rCN1 (1.6 ± 0.2mmol/mg/h/mM).
Carnosinase activity in renal kidney tissue of diabetic mice
CN1 activity in kidney tissue of db/db mice and controls at age
21weeks was dose-dependently inhibited by cysteine or GSH, but
not by GSSG (data not shown) (Figure 2). Renal CN1 activity was
higher in diabetic (db/db) mice as compared to wild-type litter-
mates (1.2 ± 0.2 vs. 0.6 ± 0.4mmol/mg/h; n¼ 3, p¼ .001). Levels of
0.3mM Cysteine or 0.5mM GSH and higher decreased CN1 activ-
ities in diabetic and control mice. The addition of 1mM GSH com-
pletely abolished CN1 activity in control mice and decreased CN1
activity reduced by more than 80% in db/db mice (0.2 ± 0.08 mmol/
mg/h).
The carnosinase–carnosine complex
Figure 3(A) shows the putative complex between carnosinase and
its natural substrate carnosine. The complex appears to be vastly
stabilized by the key ion-pair between the carnosine carboxyl
group and Arg350, while a Zn2þ ion polarizes the carbonyl group
thus facilitating water-mediated hydrolysis. The carnosine amino
group is engaged in the ionic network involving the Zn2þ ions
and in particular, approaches Asp202 and Glu451. Ser423 seems to
act as a bridge stabilizing H-bonds with both carboxyl and amino
groups. The imidazole ring of carnosine is inserted into a rather
hydrophobic cavity where it can stabilize p–p stacking with His452
plus weak H-bonds with Gln110 and Asn220. Although the con-
tacts elicited by the imidazole appear somewhat marginal, they
are, however, suitable to render the enzyme selective for histidine-
containing dipeptides.
Effect of cysteinylated residues
Besides analyzing the effects of the cysteinylated residues on car-
nosine binding, we investigated the effects of modifications of the
regions around the cysteinylated residues through MD simulations.
Figure 3(B) shows the interactions elicited by S-cysteinylated
Cys102 at the end of the simulation. Specifically, the cysteinyl
ammonium head is engaged in a clear ion-pair with Asp196, while
the carboxyl group elicits H-bonds with Ser193 and Tyr104. The
disulfide bridge is involved in H-bonds with Thr100 and Asn164
plus extended sulphur-p interactions with Tyr104. Thus, S-cysteiny-
lation induces the key approach of Asp196 and Tyr104 in a pose
stably conducive to the above-mentioned contacts. Similarly,
Figure 3(C) depicts the contacts stabilized by the cysteinylated
Table 1. Catabolic rate of serum CN1 in the presence of inhibitors (n¼ 5).
Vmax (mmol/mg/h) Km (mM) Efficiency (Vmax/Km)
Control 4.2 ± 0.4 0.8 ± 0.1 5.2 ± 0.2
Cysteine (1mM) 1.8 ± 0.2 1.0 ± 0.2 1.6 ± 0.2
N-acetylcysteine (1mM) 2.4 ± 0.2 1.1 ± 0.3 2.0 ± 0.3
GSH (1mM) 2.9 ± 0.4 0.9 ± 0.2 3.2 ± 0.4
GSSG (1mM) 4.1 ± 0.5 0.9 ± 0.3 4.6 ± 0.4
L-Glutamic acid (1mM) 4.2 ± 0.5 0.8 ± 0.2 5.2 ± 0.3
Glycine (1mM) 4.1 ± 0.4 0.7 ± 0.3 5.8 ± 0.4
Efficiency of recombinant CN1 activity were calculated by the ratio of Vmax and
Km.p< .05 compared to control.
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Figure 1. Dose-dependent effect of cysteine on recombinant CN1 activity. Levels
of 0.2mM cysteine and higher, resulted in significantly reduced CN1 activity
(n¼ 8, p< .005).
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Cys229 residue at the end of the MD run and reveals the rich
set of ion pairs that the charged termini of the cysteinyl
residue stabilize with Arg230, Glu245, Asp249 and Arg375. In con-
trast, the disulfide bridge elicits only a weak H-bond with Asn379
plus hydrophobic contacts with Val227 and Val364. The compari-
son of the first and last structures coming from the MD simulation
reveals the marked approach of the above-mentioned ionized side
chains which progressively focusing on the cysteinyl ionized
termini.
The primary objective of the reported MD simulations
involved the analysis of the effects of S-cysteinylation on carno-
sine binding with a view to explain the inhibiting effect ascrib-
able to the sole modification of Cys102. The key interactions
stabilizing the carnosinase–carnosine complex were monitored
during the two MD runs revealing the key differences between
the two cysteinylated forms which are in line with the reduced
catalytic efficacy of the S-cysteinylated Cys102 form. Indeed,
Figure 4(A) compares the time-dependent profile of the distance
between the carnosine carboxyl terminus and Arg350 as gener-
ated by the two MD runs and suggests that this key ionic con-
tact is stably and similarly retained throughout both MD runs.
In contrast, Figure 4(B) shows the corresponding distance pro-
files for the catalytically crucial interaction between the carno-
sine carbonyl group and the Zn2þ ions and reveals notable
differences between the two simulated modifications. Indeed,
such a contact is stably conserved in the S-cysteinylated Cys229
form, while it appears to be clearly weakened in the S-cysteiny-
lated Cys102 form as confirmed by the distance average (as
computed over the entire MD run) shifting from 4.26 Å to
5.98 Å. Taken together, the weakened contacts stabilized by car-
nosine in the S-cysteinylated Cys102 form is reflected by a
greater mobility of the ligand as shown in Figure 4(C) and con-
firmed by a RMSD average which shifts from 1.98Å to 3.18 Å.
The different interactions can be also evaluated by the pair
interaction calculations as implemented in Namd which com-
putes the interaction energy, as decomposed into ionic plus van
der Waals terms, by applying the same parameters with which
the MD simulations were performed. As shown in Figure 4(D),
the major difference between the two analysed simulations
involves the ionic contacts which reveal a clear (albeit not very
marked) weakening induced by the S-cysteinylation of Cys102.
The van der Waals term appears to be comparable or at most
S-cysteinylation of Cys102 induces a slight strengthening of
such contacts probably as they tend to counteract the missing
polar contacts even though the overall interaction energy con-
firms the destabilizing effects induced by S-cysteinylation of
Cys102 (results not shown).
Discussion
Since the relevance of carnosine in diabetes2,18, cancer and neuro-
logical diseases40–42 is well described, understanding the molecu-
lar basis of CN1 regulation and its effect on carnosine levels is
essential to provide potential novel therapeutic approaches. In dia-
betic mice and rats, decreased carnosine content was found in ret-
ina, kidney and liver24,26,43 whereas renal CN1 was increased21.
The increase of renal CN1 activity of diabetes is caused by post-
translational modifications, i.e. increased carbonylation and
reduced S-nitrosylation, i.e. the covalent binding of NO to cys-
teines32. CN1 activity is regulated by modifications of cysteine at
position 102, while cysteine at position 229 was shown to be
irrelevant for enzyme function32. The active site of CN1 does not
contain cysteine residues, but Cys102 is located in the same
b-strand as His106. We now demonstrate a novel mechanism of
Cys102 modification, inhibiting CN1 activity. Thiol-containing com-
pounds, such as GSH, cysteine and N-acteylcysteine, reduce CN1
activity, whereas thiol-free components such as L-glutamic acid
and glycine and oxidized glutathione, have no effect on CN1 activ-
ity. Cysteine substitution in recombinant CN1 demonstrated
the relevance of cysteinylation of cysteine at position 102 on cata-
lytic efficiency. In renal tissue homogenates of diabetic mice, the
Cysteine (mM) 0 0 0 0 0 0 0 0 0 0.3 0.5 1
GSH (mM) 0 0 0.5 1 0 0 0.5 1 2 0 0 0
GSSG (mM) 0 1 0 0 0 1 0 0 0 0 0 0
Mice --------- control ------- --------------- db/db  ---------------
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Figure 2. Dose-dependent effect of reduced glutathione (GSH) on renal CN1 activity of db/db mice and controls (at 25weeks age). Addition of GSH, but not the add-
ition of GSSG, reduced CN1 activity dose-dependently. 0.5mM GSH significantly lowered CN1 activity for control and control mice (n¼ 8; p< .005).
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addition of GSH normalized renal CN1 activity, indicating that the
ratio of reduced to oxidized glutathione is important for CN1 regu-
lation. In renal tissue of diabetic mice GSH concentrations are
inversely related to CN1 activity32.
In biological systems, thiols are found in cysteine and derived
molecules of low and high molecular weight at millimolar concen-
trations44. Cysteine plays protective roles in maintaining the redox
state by S-cysteinylation, a reversible reaction which shields pro-
tein thiols by preventing their irreversible oxidation to sulfonic
acids45. Due to its strong nucleophilicity, compared with other
amino acids, cysteine is more prone to oxidation by ROS46.
Common reversible modifications of cysteine include formation of
sulfenic acid (SOH), S-nitrosylation (SNO), S-glutathionylation (SSG),
S-palmitoylation, and the formation of disulphide bonds47. These
reversible post-translational modifications (PTMs) have important
biological roles and help maintain homeostasis by preventing the
formation of irreversible oxidative modifications [e.g. sulfinic
(SO2H) and sulfonic acid (SO3H)]48. Furthermore, these modifica-
tions are critical for cellular signalling. Metabolic imbalance result-
ing from reversible or irreversible PTMs of cysteine residues can
lead to cellular damage. Specifically, thiol-based redox regulation
is important in metabolism and dysregulated thiol redox homeo-
stasis has been implicated in aging and diseases, such as cancer,
cardiovascular, neurodegenerative diseases and diabetes46.
Thus, better understanding of the landscape of the thiol redox
proteome can give insight into biochemical events that occur in
disease, and may lead to potential biomarkers for disease diagno-
sis and therapeutic interventions.
The present study proposes a mechanism by which increased
CN1 activity can be inhibited in diabetes as well as during aging,
in order to counteract the decreasing carnosine level49, which
depends on the cysteine levels and redox state. Inhibition of CN1
activity by compounds such as N-acetylcysteine, which are
licensed for liquefaction of the mucus in bronchopulmonary dis-
ease and as antidote, e.g. in case of paracetamol intoxication,
should provide the option to increase systemic carnosine concen-
trations by oral supplementation. Augmentation of systemic histi-
dine dipeptide levels by exogenous carnosine in humans
potentially exerting protective actions as repeatedly described in
rodents lacking serum CN1, up to now where prevented by rapid
degradation by CN1. S-cysteinylation, which usually has the sole
objective of protecting key protein thiol groups, is able to allos-
terically and potently reduce CN1 enzymatic activity and thus
should increase the plasma levels of carnosine which can actively
participate in the overall antioxidant defence and cytoprotection18.
To the best of our knowledge, this is the first report documenting
that S-cysteinylation has not only a protective effect but also a
regulatory allosteric role. Previous studies suggested that it can
influence protein dimerization as seen in Cu2þ/Zn2þ-containing
superoxide dismutase-150. However, such a modulatory
Figure 3. Main interactions stabilized with carnosinase by: (A) carnosine within the catalytic pocket as computed by initial docking simulations; (B) Cys102-cysteinylated
residue as derived at the end of the MD simulation; (C) Cys229-cysteinylated residue as derived at the end of the MD simulation.
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mechanism might be shared by other S-cysteinylated proteins.
Interestingly, such a mechanism induces a transient and partial
enzymatic inhibition which would be largely favourable compared
to an irreversible and/or complete inhibition especially for those
tissues where CN1 regulates the release of GABA from homocyst-
eine. In other words, an allosteric inhibition seems to be well
suited for CN1 since it allows to finely increasing the carnosine
level without completely abolishing its enzymatic activity which
might lead to the accumulation of histidine-containing dipeptides.
S-cysteinylation reduces the maximum rate of the reaction
without changing the apparent binding affinity for carnosine (Km
value). This indicates the mechanism of noncompetitive inhibition,
involving reversible binding to an allosteric site. Allosteric ligands
influence activity by binding to sites that are topographically
distinct from orthosteric binding sites51. Allosteric sites allow effec-
tors to bind to the protein, which often results in a conformational
change involving protein dynamics. The underlying putative com-
plex between CN1 and carnosine by MD simulation is in agree-
ment with that recently proposed by Pavlin and coworkers28. The
comparison revealed that the most remarkable conformational
shift characterizing the S-cysteinylated form of Cys102 is that
involving Tyr104 which stably contacts a Zn2þ ion in the simula-
tion involving the S- cysteinylated Cys229-containing enzyme,
while in the S- cysteinylated Cys102 form it leaves the Zn2þ ion to
approach the cysteinylated residue. Such a conformational change
induces a rearrangement of the negatively charged residues sur-
rounding the Zn2þ ions which in turn causes a partial shift of the
carnosine ammonium head with the consequent distancing of the
Figure 4. Destabilizing effects of Cys102-S-Cysteinylation on carnosinase–carnosine complex as assessed by comparing the dynamic behaviour in the two performed
MD runs of (A) the distance between the carnosine’s carboxyl group and Arg350; (B) the distance between the carnosine’s carbonyl group and the Zinc ion; (C) the car-
nosine mobility as evaluated by rmsd values computed by considering only the carnosine atoms; (D) the ionic interaction energy as computed by Namd2.7.
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carbonyl group. Thus, the presented results can account for the
partial inhibition of the catalytic activity of the S-cysteinylated
Cys102 which yet retains part of its catalytic activity as suggested
by the overall limited differences detected between the two
MD runs.
Conclusions
In conclusion, we provide evidence for a novel mechanism of CN1
regulation. Kinetic parameters and MD simulations revealed that
inhibition by thiol-containing compounds is due to allosteric inter-
actions through S-cysteinylation. Recent research has pinpointed
allosteric interactions as a useful tool to modulate receptor func-
tion in ways that cannot be achieved by ligands that bind to
an orthosteric site52. Therefore, allosteric ligands can present
therapeutic advantages over orthosteric ligands. Inhibition of cir-
culating and tissue CN1, resulting in higher carnosine levels, may
represent a valuable therapeutic strategy for mitigation of compli-
cations associated with diseases such as diabetes mellitus.
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